What is Changchun BCHT Biotechnology Co.'s (688276.SS) StockRank?

MoatMap's StockRank for Changchun BCHT Biotechnology Co. (688276.SS) is 21/100, with a Sell signal. This is a composite score combining Quality (40), Value (45), and Momentum (27) factor ranks across MoatMap's 20,000+ stock universe.

Does Changchun BCHT Biotechnology Co. have an economic moat?

Changchun BCHT Biotechnology Co. (688276.SS) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Changchun BCHT Biotechnology Co. a buy, hold, or sell?

MoatMap's current signal for Changchun BCHT Biotechnology Co. (688276.SS) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Changchun BCHT Biotechnology Co. in?

Changchun BCHT Biotechnology Co. (688276.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688276.SS

SELLREMOVE

Changchun BCHT Biotechnology Co. · Healthcare · China · $975M · Avg Vol: $5M/d

StockRank

P/E (TTM)

—

ROE

-6.6%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Changchun BCHT Biotechnology is a Chinese vaccine manufacturer. It does not operate as a CDMO and is subject to intense domestic regulatory scrutiny and price controls, failing to meet our criteria for high pricing power and global scalability.

COMPANY DESCRIPTION

Changchun BCHT Biotechnology develops and manufactures human vaccines, with a core focus on varicella (chickenpox), influenza, and rabies vaccines. The company's competitive moat is established by its dominant market share in China's varicella vaccine market and its advanced live-attenuated vaccine platforms. It is a leading domestic vaccine manufacturer benefiting from high regulatory barriers and growing public health demand.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	158M	270M	182M	89M	-17.3%
EPS	0.07	0.18	0.08	-0.09	12.8%
Shares	413M	413M	414M	414M	+0.2%
Debt	107M	3M	15M	39M	-28.4%
Equity	526M	594M	623M	569M	2.7%
Op CF	6M	38M	60M	34M	79.7%
Inv CF	-43M	-94M	-80M	-67M	—
Fin CF	-6M	-6M	5M	13M	—

PRICE (1M)-22.9%

SMA 50SMA 200

$2.11

RSI (14)

24.9

52W High

$3.89

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-8.3%35.6

ROE

-6.6%38.2

GP/Assets

7.4%21.9

Op. Margin

2.5%49.8

FCF/Assets

-2.6%41.8

Piotroski

—55.7

Int. Cover

-50.0x6.4

D/E Ratio

0.08x68.6

Current Ratio

1.28x18.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-37.2x91.5

P/FCF

—N/A

P/B

1.5x65.4

P/S

10.0x25.9

Div Yield

—N/A

Momentum

52W High %

54%29.6

RS 6M

-41%30.0

SMA 50/200

0.85x21.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$975M

P/E (Forward)

—

Gross Margin

63.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688276.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688276.SS	Changchun BCHT Biotechnology Co.(you)	$975M	21	SELL
600422.SS	KPC Pharmaceuticals,Inc.	$999M	23	SELL
688221.SS	Frontier Biotechnologies Inc.	$1.1B	22	SELL
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.	$994M	25	SELL
600129.SS	Chongqing Taiji Industry(Group) Co.,Ltd	$1.2B	22	SELL
600812.SS	North China Pharmaceutical Company.Ltd	$1.2B	20	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
6185.HK	CanSino Biologics Inc.	$814M	19	STRONG SELL
688176.SS	Jiangsu Yahong Meditech Co., Ltd.	$961M	28	SELL
688621.SS	Beijing Sun-Novo Pharmaceutical Research Co., Ltd.	$894M	26	SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Changchun BCHT Biotechnology Co. (688276.SS) — Stock Score Summary

Changchun BCHT Biotechnology Co. (688276.SS) has a MoatMap StockRank of 21/100 based on Quality (40/100), Value (45/100), and Momentum (27/100) factor scores. The current signal is SELL. Changchun BCHT Biotechnology is a Chinese vaccine manufacturer. It does not operate as a CDMO and is subject to intense domestic regulatory scrutiny and price controls, failing to meet our criteria for high pricing power and global scalability.

Key Financial Metrics

Price	$2.11
Market Cap	$975M
Price/Book	1.53
Return on Equity	-6.6%
Return on Invested Capital	-8.3%
Debt/Equity	8.23
Gross Margin	63.2%
Operating Margin	2.5%
Revenue Growth	-9.2%
Free Cash Flow	$-3M

Changchun BCHT Biotechnology Co. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Changchun BCHT Biotechnology Co.’s (688276.SS) StockRank?: MoatMap’s StockRank for Changchun BCHT Biotechnology Co. (688276.SS) is 21/100, with a Sell signal. It is a composite of Quality (40), Value (45), and Momentum (27) factor ranks across MoatMap’s 20,000+ stock universe.
Does Changchun BCHT Biotechnology Co. have an economic moat?: Changchun BCHT Biotechnology Co. (688276.SS) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Changchun BCHT Biotechnology Co. a buy, hold, or sell?: MoatMap’s current signal for Changchun BCHT Biotechnology Co. (688276.SS) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Changchun BCHT Biotechnology Co. in?: Changchun BCHT Biotechnology Co. (688276.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).